We did not identify any congenital or acquired aberrations of the alternative complement pathway in this select group, suggesting the presence of dual pathologies is exceptional and that routine screening for complement mutations in TTP patients with ADAMTS‐13 levels < 10% and transient severe renal impairment is not necessary. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.